Top

Published in:

01-07-2024 | Atopic Dermatitis | Research Letter

Metabolic effects of upadacitinib in patients with psoriasis and atopic dermatitis

Authors: Marielos I. Posada Posada, Maria Beatrice Alora, Xinaida Taligare Vasconcelos Lima

Published in: Archives of Dermatological Research | Issue 5/2024

Excerpt

Upadacitinib, a selective JAK-1 inhibitor, is FDA-approved for treating psoriatic arthritis (PsA) and atopic dermatitis (AD) [1‐3]. Although found to be effective and safe in clinical trials, it has been associated with metabolic abnormalities [4, 5]. We aimed to evaluate the metabolic effects of upadacitinib in psoriasis (PsO) and AD patients in a real-world scenario. …

Calabrese L, Chiricozzi A, De Simone C, Fossati F, D’Amore A, Peris K (2022) Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Expert Opin Drug Metab Toxicol 18(5):347–355. https://doi.org/10.1080/17425255.2022.2099835CrossRefPubMed

Duggan S, Keam SJ (2019) Upadacitinib: first approval. Drugs 79:1819–1828. https://doi.org/10.1007/s40265-019-01211-zCrossRefPubMed

De Greef A, Ghislain PD, de Montjoye L, Baeck M (2023) Real-life effectiveness and tolerance of Upadacitinib for severe atopic dermatitis in adolescent and adult. Adv Ther 40(5):2509–2514. https://doi.org/10.1007/s12325-023-02490-5CrossRefPubMedPubMedCentral

Spinelli FR, Meylan F, O’Shea JJ, Gadina M (2021) JAK inhibitor: ten years after. Eur J Immunol 51(7):1615–1627. https://doi.org/10.1002/eji.202048922CrossRefPubMed

Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Agouridis AP (2022) The Effect of Upadacitinib on lipid Profile and Cardiovascular events: a Meta-analysis of Randomized controlled trials. J Clin Med 11(23):6894. https://doi.org/10.3390/jcm11236894CrossRefPubMedPubMedCentral

Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, McCaskill RM, Zueger P, Pangan AL, Tillett W (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 80(3):312–320. https://doi.org/10.1136/annrheumdis-2020-218870CrossRefPubMed

Title: Metabolic effects of upadacitinib in patients with psoriasis and atopic dermatitis
Authors: Marielos I. Posada Posada
Maria Beatrice Alora
Xinaida Taligare Vasconcelos Lima
Publication date: 01-07-2024
Publisher: Springer Berlin Heidelberg
Keywords: Atopic Dermatitis
Vulgar Psoriasis
Psoriatic Arthritis
Liver Function Test
Published in: Archives of Dermatological Research / Issue 5/2024
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-024-02892-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Metabolic effects of upadacitinib in patients with psoriasis and atopic dermatitis

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2024

An algorithmic approach to scalp reconstructive surgery: maximization of cosmetic and functional outcomes

Evaluation of risk for hepatitis B virus reactivation in patients with psoriasis treated with biologic therapies: a single-center retrospective study

Cosmeceuticals for antiaging: a systematic review of safety and efficacy

Basal cell carcinoma has greater subclinical extension than squamous cell carcinoma: a cohort study

Antibiotic adherence in dermatologic surgery: a Multicenter prospective cohort study

The ABO blood group antigens in patients with oral lichenoid reaction